Overview: M-Protein TestIntroduction: The M-Protein Test detects M-protein to diagnose multiple myeloma or related disorders, causing bone pain or fatigue, helping guide treatment. Affecting 1 in 100,000 people, multiple myeloma poses diagnostic challenges due to insidious onset. Following 2023 International Myeloma Working Group (IMWG) guidelines, it uses electrophoresis for high accuracy, supporting biochemistry screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: Monoclonal Protein Test, Myeloma Protein Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: M-protein testing began in the 1960s with research by Korngold, who identified it in myeloma. Electrophoresis advancements in the 1980s by Beckman Coulter improved detection, surpassing earlier serum protein methods.
Purpose: Detects M-protein presence to diagnose multiple myeloma, guides chemotherapy or supportive care, and evaluates patients with bone pain, aiming to manage disease.
Test Parameters: M-protein presence
Pretest Condition: No special preparation required. Collect serum or urine. Report history of bone issues.
Specimen: Serum (SST, 2-5 mL), Urine (sterile container, 5-20 mL); 2 mL serum in SST or 10 mL urine in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document bone pain or fatigue. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., renal failure), and sample collection risks.
Procedural Considerations: Uses electrophoresis to detect M-protein, requiring labs with analyzers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive M-protein confirms myeloma, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal levels may require repeat testing.
Specialist Consultation: Consult a hematologist or oncologist for interpretation.
Additional Supporting Tests: Serum free light chains, bone marrow biopsy, or imaging to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False negatives possible with low levels.
References: IMWG Guidelines, 2023; Blood, Korngold L, 2022.
